Twist Bioscience Director Sells $51,000 in Stock

Insider transaction sees 3.74% decrease in director's position

Apr. 4, 2026 at 10:43am

Got story updates? Submit your updates here. ›

Twist Bioscience Corporation (NASDAQ:TWST) Director Melissa Starovasnik sold 1,000 shares of the company's stock on April 1st, 2026 for a total transaction of $51,000. The sale represented a 3.74% decrease in Starovasnik's position, leaving her with 25,722 shares valued at $1,311,822.

Why it matters

Insider transactions, especially sales, can provide insights into how company leadership views the stock's valuation and future prospects. This sale by a Twist Bioscience director may signal some uncertainty about the company's short-term performance, though the director still maintains a sizable stake.

The details

The stock sale was executed under a pre-arranged Rule 10b5-1 trading plan, which allows company insiders to schedule stock transactions in advance to avoid concerns about trading on material non-public information. Twist Bioscience is a synthetic biology company that specializes in DNA synthesis and has seen its stock price fluctuate significantly over the past year.

  • The stock sale occurred on Wednesday, April 1st, 2026.

The players

Melissa Starovasnik

A director on the board of Twist Bioscience Corporation.

Twist Bioscience Corporation

A synthetic biology company that specializes in DNA synthesis and is publicly traded on the NASDAQ under the ticker symbol TWST.

Got photos? Submit your photos here. ›

The takeaway

This insider sale by a Twist Bioscience director, while not necessarily indicative of broader concerns, does highlight the volatility and uncertainty that can surround high-growth biotech stocks. Investors will likely continue to closely monitor Twist's financial performance and any further insider trading activity.